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Abstract
Catecholaminergic polymorphic ventricular tachycardia (CPVT) is a highly malignant inher-
ited arrhythmogenic disorder. Type 1 CPVT (CPVT1) is caused by cardiac ryanodine recep-
tor (RyR2) gene mutations resulting in abnormal calcium release from sarcoplasmic
reticulum. Dantrolene, an inhibitor of sarcoplasmic Ca2+ release, has been shown to rescue
this abnormal Ca2+ release in vitro. We assessed the antiarrhythmic efficacy of dantrolene
in six patients carrying various RyR2mutations causing CPVT. The patients underwent ex-
ercise stress test before and after dantrolene infusion. Dantrolene reduced the number of
premature ventricular complexes (PVCs) on average by 74% (range 33-97) in four patients
with N-terminal or central mutations in the cytosolic region of the RyR2 protein, while dantro-
lene had no effect in two patients with mutations in or near the transmembrane domain. In-
duced pluripotent stem cells (iPSCs) were generated from all the patients and differentiated
into spontaneously beating cardiomyocytes (CMs). The antiarrhythmic effect of dantrolene
was studied in CMs after adrenaline stimulation by Ca2+ imaging. In iPSC derived CMs with
RyR2mutations in the N-terminal or central region, dantrolene suppressed the Ca2+ cycling
abnormalities in 80% (range 65-97) of cells while with mutations in or near the transmem-
brane domain only in 23 or 32% of cells. In conclusion, we demonstrate that dantrolene
given intravenously shows antiarrhythmic effects in a portion of CPVT1 patients and that
iPSC derived CMmodels replicate these individual drug responses. These findings illus-
trate the potential of iPSC models to individualize drug therapy of inherited diseases.
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Introduction
Catecholaminergic polymorphic ventricular tachycardia (CPVT) is one of the most malignant
inherited arrhythmogenic disorders. It manifests with exercise-induced premature ventricular
complexes (PVCs), polymorphic or bidirectional ventricular tachycardia, or sudden death, usu-
ally associated with vigorous physical exercise or mental stress.[1–3] Current therapeutic op-
tions include beta-antiadrenergic drugs, flecainide, implantable cardioverter-defibrillators
(ICD) [4–6] and left cardiac sympathetic denervation.[7,8] Better antiarrhythmic medication is
still needed to minimize the need for ICD shock therapies. The most common subtype, type 1
of CPVT (CPVT1) is a dominantly inherited disease caused by mutations in the cardiac ryano-
dine receptor (RyR2) gene.[9,10] The gain-of-function mutations of RyR2 cause increased cal-
cium (Ca2+) sensitivity which can lead to spontaneous Ca2+ release from sarcoplasmic
reticulum, generation of afterdepolarizations, and triggered activity.[4,5,11]
The ryanodine receptor isoform RyR1 is the skeletal muscle counterpart in the gene family.
Mutations of RyR1 result in malignant hyperthermia, a rare but life-threatening complication
of general anesthesia occurring upon administration of volatile anesthetics or depolarizing
muscle relaxants. Dantrolene is a specific and currently the only effective treatment for malig-
nant hyperthermia.[12] Interestingly, dantrolene has also shown to exert antiarrhythmic effects
in animal models of CPVT1.[13–15] Dantrolene has been proposed to act through binding to
the N-terminal parts of RyR1 and RyR2 and restoring inter-domain interactions critical for the
closed state of the RyR2 Ca2+ channel.[16]
Several studies using induced pluripotent stem cell (iPSC) technology [17] have indicated
the ability of CPVT1 patient-specific iPSC derived cardiomyocytes (CMs) to replicate the dis-
ease phenotype in cell culture.[18–24] Dantrolene was reported to rescue the disease phenotype
in iPSCs derived CMs from a single RyR2mutation carrier [20] but no in vivo data exists on its
effects on CPVT1 patients.
In the present study, we report the proof of principle of the antiarrhythmic activity of dan-
trolene in a cohort of CPVT1 patients. In addition, we demonstrate that the in vivo drug effects
are closely reproduced in iPSC-derived patient-specific CMs, and provide evidence for muta-
tion-specific effects of dantrolene in CPVT1.
Materials and Methods
The protocol for this trial is available as supporting information; see S1 Protocol and S2
Protocol.
Clinical Study Scheme
The study was approved by the Ethical Review Committee of the Helsinki University Hospital
(HUS 396/13/03/01/12) and was in accordance with the institutional guidelines and the Decla-
ration of Helsinki. A written informed consent was obtained from all patients. Clinical trial
was registered with EudraCT (2012-005292-14). Participants were recruited between 1st March
2013 and 29th May 2014. Follow up time of the patients was three days after the dantrolene in-
fusion. Four patients participated the study at the Helsinki University Hospital and two at the
Tampere University Hospital, Heart Center. The authors confirm that all ongoing and related
trials for this drug are registered.
Patients
The study group consisted of 6 individuals (mean age 50±10 years, range 37–59 years, 5 fe-
males), who were molecularly defined heterozygous carriers of different gain-of-function RyR2
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mutations causing CPVT1. CPVT1 patients carried the following mutations: c.168-301_c.273+
722del1128mutation (later called as exon 3 deletion) or point mutations p.P2328S
(c.6982C>T), p.T2538R (c.7613C>G), p.L4115F (c.12343C>T), p.Q4201R (c.12602A>G) or p.
V4653F (c.13957G>T). Mutation nomenclature was based on RyR2 reference sequence
NM_001035.2. The mutations were located in the four mutation hotspot clusters of the RyR2
gene (Fig 1).[11] Patients and families carrying mutations P2328S [3,10,25], exon 3 deletion
[3,26], Q4201R [10,25] and V4653F [10,25] have been described in detail earlier.
All mutations were associated with exercise-induced ventricular arrhythmias and syncopal
spells. All except L4115F were associated with one or more cases of sudden death at young age
in the family. An ICD had been implanted in five of them; one has received an adequate shock
therapy. Five out of the six patients had a history of syncopal spells upon a frightening situation
or physical exercise, and they all used a beta-adrenergic blocking agent (daily dose of 160 mg of
propranolol, 7, 5 to 10 mg of bisoprolol or 95 mg of metoprolol) during all study phases. No
other medications were in use. The patients were otherwise healthy without hypertension, dia-
betes, or evidence of other heart disease. None of them had bundle branch block.
In cardiac ultrasonography, left ventricular end diastolic dimension and systolic function
were normal in all patients (data not shown). Basic laboratory parameters including hemoglo-
bin, white blood cell count, plasma sodium, potassium, and creatinine concentrations were an-
alyzed prior to administration of the drug and they were all within the normal range in every
study patient (data not shown). Two of the patients with ICD showed atrial pacing at rest prior
to exercise; all others had sinus rhythm. Electrocardiographic parameters are presented in
Table 1.
Clinical Exercise Stress Test
All RyR2 patients underwent the exercise stress test three times. On the first morning a baseline
study was carried out. The test was repeated in the afternoon of the first day after intravenous
infusion of dantrolene sodium (Dantrium, 1.5 mg per kg of body weight). The third exercise
test was performed on the second day to assess the effects after dantrolene sodium washout
and to demonstrate the reproducibility of the basic exercise test.
Exercise tests were performed with a bicycle ergometer. The initial load was 30 W, followed
by increments of the load by 15 W each minute. In the baseline study, the patient was
Fig 1. RyR2 protein, mutations studied in the present study andmutation clusters 1–4.Mutations in this
study (arrows) are located in different parts of the RyR2 protein and mutation clusters. Clusters are
represented as black lines numbered from 1 to 4. Cluster 1 comprises of amino acids (AA) 44–466, cluster 2
AA 2246–2534 and cluster 3 AA 3778–4201 and these three clusters are located in the N-terminal and
central regions of the protein and form the cytoplasmic domain. Cluster 4 comprises of AA 4497–4959 and
forms the transmembrane domain, which is located in the C-terminal region. The figure is modified from [11].
doi:10.1371/journal.pone.0125366.g001
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instructed to target to a submaximal workload in order to be able to repeat the exercise stress
test. In the consecutive phases of the study, the workload target was the same as that achieved
in the first study. A twelve-lead electrocardiogram (ECG) was recorded continuously at paper
speed 25 or 50 mms-1 and amplification of 0.1 mV/mm throughout the exercise test. After ces-
sation of exercise, ECG was recorded continuously for the first 8 minutes. Both the maximum
workload achieved and the heart rate at which ventricular bigeminy first appeared were re-
corded whenever applicable. Numbers of PVCs during exercise and at recovery phase as well as
the maximum number of consecutive PVCs were counted. Plasma creatinine, sodium, potassi-
um and calcium were measured at rest before the first exercise test. The exercise tests and the
iPSC studies were done separately and blinded.
Characterization of iPSC Lines
The iPSC study was approved by the ethical committee of Pirkanmaa Hospital District
(R08070) and written informed consent was obtained from all the participants. Patient-specific
iPSC lines were established as described earlier.[17] Studied iPSC lines were UTA.05605.CPVT
generated from patient with RyR2 exon 3 deletion, UTA.05208.CPVT from patient with muta-
tion P2328S, UTA.07001.CPVT from patient with mutation T2538R, UTA.03701.CPVT from
patient with mutation L4115F, UTA.05503.CPVT from patient with mutation Q4201R,
UTA.05404.CPVT from patient with mutation V4653F and UTA.04602.WT from a healthy
control individual.
All the CPVT-iPSC lines were characterized for their karyotypes, mutations, pluripotency,
immunocytochemistry, embryoid body (EB) and teratoma formation. Endogenous and exoge-
nous gene expressions were examined by RT-PCR using 1 μl cDNA and 500 nmol/L of each
primer in one PCR reaction. β-actin and GAPDH served as the housekeeping genes. Detailed
reaction conditions and PCR primers for iPSC characterization have been described earlier.
[27] Endogenous pluripotency markers at the protein level were studied with immunocyto-
chemistry. The iPSCs were fixed with 4% paraformaldehyde (PFA, Sigma-Aldrich, Saint Louis,
USA). Primary antibodies anti-SOX2, anti-NANOG and anti-tumor-related antigen (TRA)1-
81 (all 1:200, from Santa Cruz Biotechnology, Santa Cruz, CA, USA) and anti-OCT3/4 (1:400,
R&D Systems) were used. Cells were mounted with Vectashield (Vector Laboratories, USA)
containing DAPI for staining nuclei. To confirm the mutations of the CPVT iPSC lines with se-
quencing the DNA was isolated using DNA Tissue XS-kit (Macherey-Nagel GmbH & Co.,
Düren, Germany). The genomic region containing the expected mutation was amplified using
PCR. Each PCR product was directly sequenced in both directions using BigDye Terminator
v3.1 and ABI 3730xl DNA Analyzer (Applied Biosystems, Carlsbad, CA, USA). In addition to
Table 1. Electrocardiographic parameters.
Before dantrolene (n = 6) After dantrolene (n = 6) p-value
Heart rate (min-1) 61±5 60±5 NS
P (ms) 109±14 110±14 NS
PQ (ms) 154±31 163±34 NS
QRS (ms) 86±8 87±5 NS
QT (ms) 419±22 407±18 NS
QTc (ms) 418±35 409±35 NS
Comparison of electrocardiographic parameters of all patients before and after the dantrolene infusion. NS
indicates no signiﬁcant.
doi:10.1371/journal.pone.0125366.t001
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direct sequencing, exon 3 deletion (1128 nucleotides) was also confirmed using PCR and aga-
rose gel electrophoresis. Karyotypes of the cell lines were determined using either standard G-
banding chromosome analysis (Medix laboratories, Espoo, Finland) or KaryoLite BoBs assay
(Perkin Elmer) based on BACs-on-Beads technology (Molecular and Systems Immunology
and Stem Cell Biology, Turku Centre for Biotechnology, University of Turku, Finland). The ex-
pression of markers characteristic of ectoderm (Nestin or SOX-1), endoderm (AFP or SOX-17),
and mesoderm (VEGF-R2) development were studied from EBs maintained in EB-medium
(KO-DMEM with 20% FBS, Non-Essential Amino Acid (NEAA), L-glutamine and penicillin/
streptomycin) for 5 weeks. EB RT-PCR primers can be seen in S1 Table. The teratoma study
was approved by ELLA- Animal Experiment Board of Regional State Administrative Agency
for Southern Finland (ESAVI/6543/04.10.03/2011). IPSCs were injected into nude mice under
the testis capsule and tumor samples collected 8 weeks after injection, followed by fixation with
4% PFA and staining of the sections with hematoxylin and eosin.
Cardiomyocyte Differentiation and Characterization
iPSCs were co-cultured with murine visceral endoderm-like (END-2) cells (Humbrecht Insti-
tute, Utrecht, The Netherlands) to differentiate them into spontaneously beating CMs. The
beating areas of the cell colonies were mechanically excised and treated with collagenase A
(Roche Diagnostics).[28] Single CMs were immunostained with anti-cardiac-troponin-T
(1:1500, Abcam, Cambridge, MA, USA), anti-α-actinin (1:1500, Sigma) and anti-connexin-43
(1:1000, Sigma).
Ca2+ Imaging
Dissociated spontaneously beating CMs on a coverslip were loaded with 4 μmol/L Fura 2-AM
(Life Technologies, Molecular Probes). CMs were continuously perfused with 37°C HEPES
based perfusate during measurements and the perfusate consisted of (in mmol/L): 137 NaCl,
5 KCl, 0.44 KH2PO4, 20 HEPES, 4.2 NaHCO3, 5 D-glucose, 2 CaCl2, 1.2 MgCl2 and 1 Na-pury-
vate (pH was adjusted to 7.4 with NaOH). Ca2+ measurements were conducted on an inverted
IX70 microscope (Olympus Corporation, Hamburg, Germany) and cells were visualized with
UApo/340 x20 air objective (Olympus). Images were acquired with an ANDOR iXon 885 CCD
camera (Andor Technology, Belfast, Northern Ireland) synchronized with a Polychrome V
light source by a real time DSP control unit and TILLvisION or Live Acquisition software
(TILL Photonics, Munich, Germany). Fura 2-AM in CMs was excited at 340 nm and 380 nm
light and the emission was recorded at 505 nm. For Ca2+ analysis, regions of interest were se-
lected for spontaneously beating cells and background noise was subtracted before further data
processing. The Ca2+ levels are presented as fura ratio units of F340/F380. Ca2+ peaks were ana-
lyzed with Clampfit version 10.2 (Molecular Devices, USA).
The percentage of abnormal Ca2+ transients, such as multiple peaks comprising of two
peaks, irregular phases, oscillations, and varying amplitude manifested as low peaks, were
calculated from each studied cell line. Beating frequency and diastolic Ca2+ levels of CMs were
analyzed during spontaneous baseline beating, and during adrenaline perfusion. These param-
eters were compared between mutated and control cell lines and also between each mutated
cell line. Some results of Ca2+ cycling of CPVT-P2328S and control cell lines have been pub-
lished before [21] and parts of these results have been included here.
For dantrolene studies, the changes in Ca2+ were recorded during spontaneous baseline
beating, spontaneous beating during 1 μM adrenaline perfusion and spontaneous beating
during 1 μM adrenaline together with 10 μM dantrolene (Sigma) perfusion. If a CM displayed
Ca2+ transient abnormalities during adrenaline perfusion, it was exposed to dantrolene. Drug
Antiarrhythmic Effect of Dantrolene with CPVT
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effects of dantrolene were categorized into three groups. In “responder” group dantrolene abol-
ished virtually all the Ca2+ handling abnormalities, in “semi-responder” group dantrolene re-
duced them by more than 50%, in “non-responder” group dantrolene reduced them by less
than 50%. Diastolic Ca2+ levels and beating frequency were compared between adrenaline and
dantrolene responses of responder CMs (exon 3 del, P2328S, T2538R, L4115F) and non-re-
sponder CMs (Q4201R, V4653F, controls). For this, adrenaline response values were divided
by dantrolene response values, separately for each cell.
Statistical Analysis
Statistical analysis of in vivo studies was made with SPSS 21.0 statistical software package
(SPSS, Chicago, IL). Data are presented as average + 1 SD. Comparisons between phases were
performed by the non-parametric Wilcoxon test. The significance of in vitro differences be-
tween two groups was evaluated with the unpaired Student’s t-test. The significance of
changes within a group was evaluated with the paired Student’s t-test. Data are expressed as
average ± S.E.M. and n refers to the number of cells. P<0.05 was considered statistically signifi-
cant in both in vivo and in vitro.
Results
Antiarrhythmic Effects of Dantrolene in Cpvt1 Patients
In the baseline study, patients exercised on an average 8±2 minutes reaching a maximum heart
rate of 134±17 min-1. Exercise bicycle testing induced polymorphic PVCs in all patients and
non-sustained ventricular tachycardia (NSVT, episodes of 3 to 4 consecutive PVCs) in three of
them. The average threshold sinus rate for the appearance of PVCs was 105±9 min-1. The total
count of PVCs during the workload was 172±119 (range 43–391).
All six patients tolerated the target dose 1.5 mg/kg of intravenous infusion of dantrolene but
reported considerable muscle weakness as a side-effect. Dantrolene did not affect atrioventricu-
lar conduction or the QT interval (Table 1). Dantrolene decreased the prevalence of PVCs in
four patients, whereas in two patients the number of PVCs remained virtually the same (Fig 2).
Dantrolene seemed to reduce arrhythmias in patients with the mutation in the N-terminal or
central region of the RyR2 protein (Figs 1 and 2). Thus, dantrolene abolished 97% of PVCs in
the patient with exon 3 deletion (cluster 1), 88% of PVCs in the patient with P2328Smutation
(cluster 2), 33% of PVSc in the patient with T2538Rmutation (right after cluster 2) and 77% of
PVCs in the patient with L4115Fmutation (cluster 3). In contrast, dantrolene abolished only 1
to 2% of PVCs in patients carrying mutation closer to (Q4201R, end of cluster 3) or within the
transmembrane region (V4653F, cluster 4).
Fig 3 illustrates an example of the PVCs and NSVT episodes during the baseline study and
after dantrolene. Dantrolene increased significantly the threshold at which the arrhythmias ap-
peared from 105±9 to 120±17 min-1. The duration of the exercise phase and the maximal
heart rate achieved during the exercise were similar to those in the baseline study. On day 2,
after wash-out of dantrolene, the prevalence of PVCs was approaching that in the first
baseline test.
Characterization of iPSC Lines Confirms Pluripotent Stem Cell
Characteristics
iPSC lines from six CPVT1 patients with above-mentioned RyR2mutations were generated.
Results of the P2328S and control iPSC line characterizations have been published before.
[21,27] All studied endogenous pluripotency genes (Nanog, Rex1, Oct 3/4 and Sox2) were
Antiarrhythmic Effect of Dantrolene with CPVT
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turned on and the expression of retrovirally encoded reprogramming factors c-Myc, Klf4, Sox2
and Oct 3/4 was silenced (Fig 4A and 4B). CPVT1 iPSC lines expressed endogenous pluripo-
tent markers Nanog, Oct3/4, TRA 1–81 and SOX2 also at the protein level (Fig 4D). Pluripo-
tency was further confirmed by teratoma formation and with in vitro embryoid body (EB)
formation expressing all three germ layers (Figs 4C and 5G). The presence of the RyR2muta-
tions was confirmed from all the CPVT1 iPSC lines with DNA sequence analysis (Fig 4E). All
the iPSC lines had a normal karyotype (Fig 4F). In addition to sequencing, the presence of the
exon 3 deletion was confirmed with PCR (S1 Fig).
iPSC Derived Cms Display Abnormal Ca2+ Cycling
iPSCs were differentiated into spontaneously beating CMs (Fig 5A). When compared to CMs
derived from the healthy individual, CPVT1 CMs demonstrated marked Ca2+ transient abnor-
malities such as multiple peaks comprising of two peaks, irregular phases, oscillations, and
varying amplitude manifested as low peaks (Fig 5B) both in baseline and in response to adrena-
line. Although these abnormalities were common with all six mutations examined, some differ-
ences between RyR2mutations were also observed. Accordingly, Ca2+ transient abnormalities
were somewhat more common in the cluster 4 mutation than in cluster 1, 2 and 3 mutations
(Fig 5C).
Adrenaline increased the beating frequency of each cell line studied (Fig 5D). All RyR2mu-
tated CMs had lower beating frequency both at baseline and during adrenaline perfusion than
control CMs. Adrenaline produced significantly elevated diastolic Ca2+ levels only in P2328S
CMs, while diastolic Ca2+ levels were lower or similar in other mutant CMs compared to con-
trol CMs (Fig 5E). Exon 3 deletion CMs had both lower beating frequency and diastolic Ca2+
level when compared to other mutations (Fig 5 and S2 Table).
Fig 2. Features of the PVCs.Number of PVCs in exercise stress test before and after administration of intravenous dantrolene and 24 hours after
dantrolene wash out.
doi:10.1371/journal.pone.0125366.g002
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iPSC Derived Cpvt1 Cms Reproduced the Clinical Antiarrhythmic
Responses to Dantrolene
Effects of dantrolene were divided into three groups based on their Ca2+ responses. In “re-
sponder” group dantrolene abolished all the Ca2+ handling abnormalities, in “semi-responder”
group dantrolene reduced them by more than 50% and in “non-responder” group dantrolene
reduced them by less than 50%. iPSC derived CMs were found to markedly reproduce the vary-
ing individual clinical responses of dantrolene (Fig 6). In cell lines with the mutation in the N
terminal or central region of the RyR2 protein dantrolene abolished or reduced the majority of
Ca2+ transient abnormalities (Fig 6). These mutations were within or in close proximity of clus-
ters 1, 2 or 3 (Fig 1). A detailed analysis indicated that in CMs with exon 3 deletion, P2328S,
T2538R or L4115F, dantrolene abolished or reduced by more than 50% of Ca2+ abnormalities
in 65–97% of cells (Fig 6).
In striking contrast, the effect of dantrolene was only minimal in CMs carrying a mutation
at the end of cluster 3 (Q4201R) or in the transmembrane region (cluster 4, mutation V4653F)
(Fig 6), in accordance with the in vivo dantrolene infusion data. Dantrolene had no effect on
the Ca2+ transients in control CMs. Dantrolene did not significantly affect the diastolic Ca2+
levels of CMs in which Ca2+ transient abnormalities were abolished (S2 Fig). Dantrolene in-
creased significantly the diastolic Ca2+ levels of control and Q4201R CMs where Ca2+ transients
were unaltered by the drug. There was no correlation between the antiarrhythmic effect of dan-
trolene and its effect on beating frequency (S2 Fig).
Discussion
We have studied the antiarrhythmic potential of dantrolene in the treatment of CPVT1. To
this end, we assessed the efficacy of intravenously administered dantrolene in patients carrying
various RyR2mutations and compared these effects to in vitro studies using iPSC derived CMs
generated from the same patients. Our findings demonstrate that intravenous dantrolene, a
drug used to treat another ryanodine receptor disorder, malignant hyperthermia, abolished or
markedly reduced arrhythmias in a subgroup of CPVT1 patients with specific RyR2mutations.
By combining evidence from in vivo and in vitro studies, we propose that the location of the
RyR2mutation affects the antiarrhythmic effect of dantrolene in CPVT1.
Previously dantrolene has been shown to have beneficial effects on cardiac function in ex-
perimental animal models of CPVT1 [13–15,29,30] and in iPSC derived CMs from a CPVT1
patient with an N-terminal S406Lmutation [20], but no studies in patients have so far been re-
ported. It is also important to take into consideration that even if a drug is found to be benefi-
cial in the patient-derived iPSC-CMs, it cannot be automatically concluded that this will
translate into a clinical benefit. Here we show that dantrolene given intravenously has an anti-
arrhythmic effect also in some but not in all patients with CPVT1. This antiarrhythmic effect
was observed only in patients with RyR2mutations in the N-terminal or central regions of
RyR2 protein (clusters 1–3), whereas virtually no effect was seen in patients carrying mutations
at the end of cluster 3 or in the transmembrane region (cluster 4). Although a dose-dependent
effect cannot be excluded, similar observations on mutation-specific drug responses have been
obtained in some other genetic disorders including long QT syndrome type 3 [31], cystic fibro-
sis [32], as well as in certain neoplastic diseases.[33] Recognition of potential mutation-specific
Fig 3. ECG examples of a 38-year-old patient carrying the RyR2 P2328Smutation. (A) Resting ECG showing sinus rhythm and normal QRS
morphology. (B) Exercise ECG at the highest work load of 105W in the baseline study before dantrolene. PVCs include couplets and polymorphic NSVTs.
(C) Disappearance of ventricular arrhythmias after administration of dantrolene (work load 105W). (D) Exercise test on day two after 20-hours wash-out of
dantrolene showing return of PVCs (work load 105W).
doi:10.1371/journal.pone.0125366.g003
Antiarrhythmic Effect of Dantrolene with CPVT
PLOSONE | DOI:10.1371/journal.pone.0125366 May 8, 2015 9 / 17
Antiarrhythmic Effect of Dantrolene with CPVT
PLOSONE | DOI:10.1371/journal.pone.0125366 May 8, 2015 10 / 17
responses will be important for future drug development: one drug may not work for all pa-
tients even if the phenotype is the same.
Currently, beta-antiadrenergic medication is the first line antiarrhythmic treatment for all
CPVT patients. Flecainide has also shown beneficial effects.[34,35] ICDs are used if severe ar-
rhythmic events occur despite optimal beta-blocking treatment. However, use of ICDs is not
without risk since ICD-shocks may further aggravate catecholamine release and initiate an un-
controlled electric storm. Very recent data suggest that left cardiac sympatectomy may be high-
ly effective in patients refractory to medical therapy.[7,36] Although dantrolene as such would
not be suitable for long-term treatment of CPVT1 due to its side effects, and although only a
subset of patients would benefit from it, our data shows its antiarrhythmic potential. It also
suggest that it could be administered by intravenously to CPVT1 patients in emergencies such
as incessant ventricular tachycardia.
Fig 4. Characterization of CPVT1 iPSCs. (A) Expression of pluripotency markers shown by RT-PCR, β-actin or GAPDH serving as a housekeeping gene.
(B) None of the exogenous genes are expressed in CPVT1 cell lines. (C) EBs express markers from all the three embryonic germ layers. (D)
Immunocytochemical stainings and expression of pluripotency markers. Scale bar 200 μm. (E) Sequencing analysis confirmed the RyR2mutation in each
cell line. (F) All the cell lines had normal karyotype, example picture fromQ4201R cell line. (G) Teratomas made from a CPVT-iPSC line further confirms
pluripotency, example pictures from L4115F cell line.
doi:10.1371/journal.pone.0125366.g004
Fig 5. Characterization of CPVT-iPSCs derived CMs. (A) Immunocytochemical stainings of cardiac markers where red represents troponin T, green
connexin-43 and blue DAPI-staining for nuclei. Scale bars 200 μm. (B) Representative traces of a control CM showing normal regular Ca2+ transients and
CPVT1 CMs showing abnormalities like multiple peaks, low peaks, irregular phases and oscillations in Ca2+ handling. (C) Quantification of percentage of
CPVT1 and control iPSC CMs exhibiting abnormal Ca2+ transients at baseline (bl) and during adrenaline perfusion (adr). (D) Frequency and (E) Diastolic
level of intracellular Ca2+ of all CPVT1 and control CMs. Numbers of cells analyzed in C, D, and E, exon 3 del n = 48, P2328S n = 72, T2538R n = 52, L4115F
n = 110,Q4201R n = 63, V4653F n = 29, Controls (WT) n = 28. As an exception, number of WT cells analyzed in D, and E, in bl n = 54 and adr n = 27 and
number of P2328S cells in bl n = 90 and adr n = 47. Grey bars indicate cells at baseline and black bars during adrenaline perfusion. Error bars, SEM. *P<0.05
CPVT1 versus control, with Student’s t-test. Significance’s of mutation specific differences, see S2 Table.
doi:10.1371/journal.pone.0125366.g005
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Fig 6. iPSC derived CMs reproduced the clinical responses of dantrolene. (A) In vivo and in vitro effects of dantrolene correspond within each RyR2
mutation. In vitro drug effects were categorized into three groups (responders, semi-responders and non-responders) depending on how dantrolene affected
to the amount of Ca2+ abnormalities when compared to adrenaline response. In vivo responder group show the percentage of the abolished PVCs when
compared to the baseline. Numbers of cells analyzed in exon 3 del n = 16, P2328S n = 32, T2538R n = 17, L4115F n = 36,Q4201R n = 22, V4653F n = 13. (B)
Antiarrhythmic Effect of Dantrolene with CPVT
PLOSONE | DOI:10.1371/journal.pone.0125366 May 8, 2015 12 / 17
More than 150 mutations in RyR2 gene have been reported so far and they are clustered in
four hotspots.[11] One third of the reported mutations are in clusters 1 and 2 and the rest are
equally distributed between clusters 3 and 4. Only 10% of RyR2mutations have been found
outside these clusters.[11] The location of the RyR2mutation appears to be critical for a favor-
able effect of dantrolene. The binding site for dantrolene is localized in the N-terminus of RyR2
between amino acid 601 and 620.[13,37] The dantrolene-binding sequence is considered to
constitute part of the domain switch region, suggesting that dantrolene is involved in the cor-
rection of defective unzipping and allosteric stabilization of interdomain interactions between
the N- terminal and central regions of RyR2, resulting in inhibition of Ca2+ leak [16,30,38] and
in fact, this has been demonstrated in previous studies.[13,16,37] Also our data demonstrate
that dantrolene abolished arrhythmias in CPVT1 patients with mutations of N terminal or cen-
tral domain, suggesting that a defective inter-domain interaction within the RyR2 could be the
underlying arrhythmogenic mechanism in the exon 3 deletion, P2328S, T2538R and L4115F.
However, dantrolene did not suppress T2538R-related arrhythmias to the same extent as ar-
rhythmias caused by other central region mutations. It has been speculated that differences in
the mode of interdomain interaction in dantrolene binding regions may result in differences in
its antiarrhythmic efficacy.[30] Furthermore, other drug-binding regions in the carboxyl-ter-
minal half of the RyR2 or additional low affinity drug binding sites in the N-terminal area
could exist.[13] No previous studies on the effects of dantrolene on RyR2mutations in or close
to the transmembrane are available; here we show that dantrolene has no or only minimal ef-
fect on arrhythmias if mutations are located in these areas. It is interesting that the patient with
Q4201Rmutation did not respond to dantrolene even though this mutation is located in cyto-
solic portion of RyR2 and in cluster 3 although in its terminal part. This finding indicates that
the location of the mutation in certain mutation cluster does not necessarily determine the an-
tiarrhythmic response, and highlights the utility of the iPSC model for individual functional
analysis.
Our data showing similar patient-to-patient variation in dantrolene effects in the clinical
setting and corresponding iPSC-CMmodels suggest that, at least in theory, it may be possible
to tailor an individual's medication in cell culture without predisposing the individual to the
potentially serious side-effects of a drug. Dantrolene did not affect normally beating CMs. This
is consistent with previous reports showing that dantrolene inhibits only abnormal Ca2+ release
and has no effect on the normal Ca2+ transients, suggesting that the native conformation of
RyR2may restrict binding of the drug and that dantrolene binding to RyR2might be dependent
on a specific conformational state present only in mutated cells.[13,37] Defective calmodulin
binding caused by RyR2 domain unzipping has also been shown to be restored by dantrolene
[29,39] which may as well explain why dantrolene exerts effects on diseased but not healthy
hearts.
Besides differences in drug responses, we also saw both similarities and differences in the
CPVT1 in vitro phenotypes depending on the nature of the mutation. The beating frequency of
CPVT1 CMs was lower than that in control CMs. This is in line what has been reported also
with CPVT1 patients.[5,40] All the CPVT1 CMs showed similar disturbances in intracellular
Ca2+ cycling. Ca2+ transient abnormalities were somewhat more common in the cluster 4 mu-
tation than in cluster 1, 2 and 3 mutations. Exon 3 deletion differed from all the other muta-
tions by having lower diastolic Ca2+ levels and beating frequency both at baseline and during
Representative traces of dantrolene responder in vitro in an L4115Fmutated CM. Adrenaline causes Ca2+ cycling abnormalities and dantrolene abolishes all
the abnormalities. (C) Representative traces of semi-responder in vitro in a P2328Smutated CM. The cell has abnormal Ca2+ cycling at baseline and during
adrenaline perfusion and dantrolene reduces the abnormalities by abolishing the oscillation but leaving some low peak Ca2+ spiking.
doi:10.1371/journal.pone.0125366.g006
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adrenaline perfusion. Exon 3 encodes secondary structure elements that are crucial for folding
of the N-terminal domain. It has been proposed that RyR2 with exon 3 deletion has evolved ad-
ditional means to regulate Ca2+ release, by altering the conformation of the domain [41], which
may result in the observed differences in Ca2+ transients.
There are certain limitations in our study. First, only six CPVT1 patients and their iPSC cell
lines were studied; however, we emphasize that despite the very rare nature of this disease we
were able to examine in detail six different disease-causing mutations. Second, under the condi-
tions of the study design we were permitted to study only acute effects of intravenously admin-
istered dantrolene. Third, although we titrated the dose of dantrolene according to the weights
of the patients, serum levels of the drug were not measured and could have varied from patient
to patient, resulting in concentration-dependent variation in clinical responses. Fourth, we
used only a fixed concentration of dantrolene, selected on the basis of the work by Jung et al.
[20], in our iPSC studies. Fifth, immature phenotype of the iPSC-CMs may produce variation
in arrhythmias. However, in our previous study [21] the electrophysiology of CPVT1
iPSC-CMs appeared fairly mature. We have also shown here and in our previous study [21]
that arrhythmias are substantially more consistent in CPVT1 CMs than in control CMs.
In conclusion, we have shown here the proof of principle that intravenously administered
dantrolene suppresses ventricular arrhythmias in the congenital RyR2 defect and that the loca-
tion of the RyR2mutation may affect the antiarrhythmic effect of this drug. We also demon-
strate that iPSC derived patient-specific CMs correctly predict the clinical response to
dantrolene in CPVT1 patients with varying RyR2mutations. Our data support the notion that
iPSC-derived CMs could serve as a platform for drug development and for design of
personalized medication.
Supporting Information
S1 Fig. Confirmation of exon 3 deletion. Exon 3 deletion of 05605. CPVT cell line was also
confirmed with PCR and agarose gel electrophoresis.
(TIF)
S2 Fig. Ca2+ transient parameters as a response to dantrolene. (A) Diastolic Ca2+ level and
(B) beating frequency in responder and non-responder CMs. Values during adrenaline perfu-
sion were divided by values during dantrolene perfusion, separately for each cell. Green bars in-
dicate responder CMs and purple bars non-responder CMs. Error bars, SEM.  indicates
significant difference between adrenaline versus dantrolene within a group, P<0.05. Numbers
of cells analyzed in exon 3 del n = 13, P2328S n = 29, T2538R n = 11, L4115F n = 28, Q4201R
n = 15, V4653F n = 10, Control (WT) n = 20.
(TIF)
S1 Protocol. English translated trial study protocol.
(DOCX)
S2 Protocol. Trial study protocol in the original language (Finnish).
(DOC)
S1 Table. Primer sequences for EB RT-PCR.
(DOCX)
S2 Table. Differences between RyR2 mutations in their Ca2+ transient properties during
baseline and adrenaline perfusion. CL indicates cluster numbers. Upward pointing arrow in-
dicates significantly (p<0.05) higher and downward pointing arrow significantly lower diastol-
ic Ca2+ level or beating frequency of the first mentioned mutation when compared to the
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second mentioned mutation. NS indicates that there was no statistical significance between
mutations. As parallel pointing arrows between comparison groups indicate, the average of the
beating frequency and diastolic Ca2+ level inside one mutation group corresponded and the av-
erage of these parameters decrease when moving from P2328S towards transmembrane
area mutations.
(DOCX)
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